CN Patent

CN1524079A — 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用

Assigned to Actelion Pharmaceuticals Ltd · Expires 2004-08-25 · 22y expired

What this patent protects

本发明涉及新颖的磺酰胺类化合物及其作为活性组分在制备药物组合物中的应用。本发明还涉及相关的方面包括：这些化合物的制备工艺，包含一种或多种符合通式I的化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的应用。

USPTO Abstract

本发明涉及新颖的磺酰胺类化合物及其作为活性组分在制备药物组合物中的应用。本发明还涉及相关的方面包括：这些化合物的制备工艺，包含一种或多种符合通式I的化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN1524079A
Jurisdiction
CN
Classification
—
Expires
2004-08-25
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.